2023
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer
Licata L, Viale G, Giuliano M, Curigliano G, Chavez-MacGregor M, Foldi J, Oke O, Collins J, Del Mastro L, Puglisi F, Montemurro F, Vernieri C, Gerratana L, Giordano S, Rognone A, Sica L, Gentilini O, Cascinu S, Pusztai L, Giordano A, Criscitiello C, Bianchini G. Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer. Npj Breast Cancer 2023, 9: 51. PMID: 37291235, PMCID: PMC10250312, DOI: 10.1038/s41523-023-00559-6.Peer-Reviewed Original ResearchEarly-stage breast cancerAdjuvant chemotherapy recommendationsChemotherapy recommendationsOncotype DX resultsClinicopathologic featuresRecurrence scorePhysician uncertaintyBreast cancerDiscordant recommendationsAdjuvant chemotherapy resultsAddition of chemotherapyChemotherapy resultsOncotype DXInstitutional databasePhysician judgmentBreast oncologistsClinical practiceOncologistsCancerAssay resultsRS resultsChange recommendationsPredictive informationChemotherapyRecommendations
2020
Impact of oncotype DX on agreement and confidence in adjuvant treatment decision making in breast cancer
Licata L, Viale G, Criscitiello C, Giordano A, Chavez-MacGregor M, Curigliano G, Foldi J, Oke O, Giuliano M, Collins R, Del Mastro L, Puglisi F, Montemurro F, Vernieri C, Gerratana L, Giordano S, Rognone A, Sica L, Pusztai L, Bianchini G. Impact of oncotype DX on agreement and confidence in adjuvant treatment decision making in breast cancer. Annals Of Oncology 2020, 31: s317-s318. DOI: 10.1016/j.annonc.2020.08.309.Peer-Reviewed Original Research
2015
Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers
Khan SS, Karn T, Symmans WF, Rody A, Müller V, Holtrich U, Becker S, Pusztai L, Hatzis C. Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers. Breast Cancer Research And Treatment 2015, 149: 789-797. PMID: 25651779, DOI: 10.1007/s10549-015-3277-7.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalAdjuvant chemotherapyEndocrine therapyHigh riskOncotype DXBreast cancerEstrogen receptor-positive breast cancerReceptor-positive breast cancerRisk categoriesEarly-stage estrogen receptorEndocrine therapy sensitivityGood prognosis patientsER-positive patientsHigh-risk patientsPoor prognosis groupPositive breast cancerLow-risk groupAdjuvant endocrineMultimodality therapyPrognosis patientsRisk patientsEndocrine sensitivityIndependent predictorsPrognosis groupT stage
2013
A comparative analysis of distant recurrence risk assessments by Oncotype DX recurrence score alone and integrated with clinicopathologic factors in early-stage breast cancer.
Kelly C, Beamish R, McCaffrey J, SMITH M, Crown J, O'Connor M, McGee S, O'Reilly S, Moylan E, Gonzalez-Angulo A, Litton J, Pusztai L, Kelly C. A comparative analysis of distant recurrence risk assessments by Oncotype DX recurrence score alone and integrated with clinicopathologic factors in early-stage breast cancer. Journal Of Clinical Oncology 2013, 31: 598-598. DOI: 10.1200/jco.2013.31.15_suppl.598.Peer-Reviewed Original ResearchRisk of recurrenceOncotype DX recurrence scoreRecurrence scoreDX recurrence scoreClinicopathologic factorsBreast cancerRecurrence risk assessmentDistant recurrenceNode negativeIR groupOncotype DXRisk groupsHER-2 negative breast cancerHER2-negative breast cancerEarly-stage breast cancerProportion of patientsOncotype DX testingNegative breast cancerChemotherapy benefitNodal statusPatient chartsTumor sizeClinical trialsAcademic hospitalLR group
2012
A dendritic metagene that predicts prognosis and endocrine resistance in breast cancer.
Giampaolo B, Pusztai L, Qi Y, Iwamoto T, Kelly C, Zambetti M, Symmans W, Gianni L. A dendritic metagene that predicts prognosis and endocrine resistance in breast cancer. Journal Of Clinical Oncology 2012, 30: 545-545. DOI: 10.1200/jco.2012.30.15_suppl.545.Peer-Reviewed Original ResearchHazard ratioEndocrine resistanceBreast cancerNeoadjuvant endocrine therapyProliferative breast cancersAdjuvant tamoxifenEndocrine therapyDistant relapseFree survivalUntreated patientsBetter prognosisDendritic cellsEarly relapseOncotype DXPoor prognosisClinical variablesPoor responseUntreated tumorsLower riskMetagene signaturePredictive valueMultivariate analysisTumorsRelapsePrognosis
2010
Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor‐positive, HER2‐normal, grade II, lymph node‐negative breast cancers
Kelly CM, Krishnamurthy S, Bianchini G, Litton JK, Gonzalez‐Angulo A, Hortobagyi GN, Pusztai L. Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor‐positive, HER2‐normal, grade II, lymph node‐negative breast cancers. Cancer 2010, 116: 5161-5167. PMID: 20665886, DOI: 10.1002/cncr.25269.Peer-Reviewed Original ResearchConceptsTrial Assigning Individualized OptionsRisk of recurrenceOncotype DXRecurrence scoreBreast cancerIntermediate riskGrade I/II tumorsLymph node-negative breast cancerNode-negative breast cancerStage I/IID. Anderson Cancer CenterOncotype DX breast cancerRisk estimatesIntermediate-risk populationEarly breast cancerRoutine clinical variablesHigh-risk groupOncotype DX testingAnderson Cancer CenterAdjuvant chemotherapyDistant recurrenceConsecutive patientsII tumorsClinicopathological variablesLobular carcinoma
2008
Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer
Ross JS, Hatzis C, Symmans WF, Pusztai L, Hortobágyi GN. Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer. The Oncologist 2008, 13: 477-493. PMID: 18515733, DOI: 10.1634/theoncologist.2007-0248.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBreast NeoplasmsCost-Benefit AnalysisDevice ApprovalFemaleGene Expression ProfilingHumansMolecular Diagnostic TechniquesParaffin EmbeddingPredictive Value of TestsPrognosisReceptors, EstrogenReverse Transcriptase Polymerase Chain ReactionUnited StatesUnited States Food and Drug AdministrationConceptsQuantitative multiplex real-time polymerase chain reactionLymph node positiveValidation clinical trialEfficacy of tamoxifenER-positive patientsPredictive testRegulatory approval statusOncotype DX testCurrent clinical utilityReal-time polymerase chain reactionCytochrome P450 CYP2D6High accrual rateMultiplex real-time polymerase chain reactionParaffin-embedded tissuesThird-party payorsProspective trialYounger patientsNode positiveClinical outcomesOncotype DXPatient eligibilityMultigene assaysPolymerase chain reactionClinical trialsBreast cancerHistopathologic and Molecular Markers of Prognosis and Response to Therapy
Pusztai L, Symmans W. Histopathologic and Molecular Markers of Prognosis and Response to Therapy. MD Anderson Cancer Care Series 2008, 323-343. DOI: 10.1007/978-0-387-34952-7_11.Peer-Reviewed Original ResearchLymph node-negative breast cancerNode-negative breast cancerBreast cancerEndocrine therapyMultigene assaysValuable additional prognostic informationAdditional adjuvant chemotherapyPrognosis of womenAdjuvant endocrine therapyLymph node statusSurgical margin statusAdditional prognostic informationRoutine pathologic evaluationPersonalized treatment recommendationsAppropriate treatment decisionsAdjuvant chemotherapyMargin statusPathologic evaluationTrastuzumab therapyBetter prognosisNode statusOncotype DXTumor sizeHistopathologic subtypeProgesterone receptor